Medtronic's Cardiac Ablation Revenue Doubles, Captures 8% US Market Share in Q4
MDT is trading near its 52-week low of $73.31 (5.6% above the low).
Summary
Medtronic's Cardiac Ablation Solutions segment reported a significant operational win in Q4, with U.S. revenue more than doubling and an 8-point gain in U.S. market share. This strong performance, driven by the Affera mapping and ablation system, was a key contributor to the company's overall cardiovascular portfolio organic growth of 10.1% for the quarter. This news provides specific detail and validation for the strong Q4 earnings and organic revenue growth reported earlier today, highlighting successful product rollout and market penetration in a critical segment.
At the time of this announcement, MDT was trading at $77.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $99.3B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.